
Bone Biologics Corp
BBLG · NASDAQ · Healthcare / Biotechnology
Price History
Full chartMarket Stats
About
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides target specific control over bone regeneration. The company also develops NB1, a NELL-1/DBM fusion device for use in lumbar spinal fusion, as well as spine implants, non-union trauma cases, and osteoporosis applications. It serves spine surgeons and patients with a skeletal bone defect or bone-related condition in their spine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion by local administration, osteoporosis, and trauma applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
Company Details
- SectorHealthcare
- IndustryBiotechnology
- CEOMr. Jeffrey Frelick
- Employees2
- Headquarters2 Burlington Woods Drive, Burlington, MA, United States, 01803, USA
- Websitehttps://www.bonebiologics.com
Leadership
- Mr. Jeffrey FrelickCEO & President · b. 1966
- Ms. Deina H. Walsh C.P.A.Chief Financial Officer · b. 1964
Financials
Income Statement
Balance Sheet
Cash Flow
Earnings
Key Statistics & Ratios
Analyst Ratings
- Strong Buy1
Ownership Breakdown
- Institutions
- 5.01%
- Insiders
- 0.02%
- Retail / Other
- 94.97%
Top Institutional Holders
- Citadel Advisors Llc23.88K1.19%
- Tower Research Capital LLC4.13K0.21%
- SBI Securities Co Ltd2300.01%
- UBS Group AG560.00%
- DRW Securities, LLC00.00%
- Two Sigma Investments LLC00.00%
- Bank of America Corp00.00%
Top Fund Holders
- Fidelity Extended Market Index7.81K0.39%
- Fidelity Total Market Index6560.03%
Stock Splits
- Jun 10, 20251:6
- Dec 20, 20231:8
- Jun 7, 20231:30